Update on Dihydropteroate Synthase (DHPS) Mutations in Pneumocystis jirovecii.

Abstract

A Pneumocystis jirovecii is one of the most important microorganisms that cause pneumonia in immunosupressed individuals. The guideline for treatment and prophylaxis of Pneumocystis pneumonia (PcP) is the use of a combination of sulfa drug-containing trimethroprim and sulfamethoxazole. In the absence of a reliable method to culture Pneumocystis, molecular techniques have been developed to detect mutations in the dihydropteroate synthase gene, the target of sulfa drugs, where mutations are related to sulfa resistance in other microorganisms. The presence of dihydropteroate synthase (DHPS) mutations has been described at codon 55 and 57 and found almost around the world. In the current work, we analyzed the most common methods to identify these mutations, their geographical distribution around the world, and their clinical implications. In addition, we describe new emerging DHPS mutations. Other aspects, such as the possibility of transmitting Pneumocystis mutated organisms between susceptible patients is also described, as well as a brief summary of approaches to study these mutations in a heterologous expression system.

• Authors: Carmen de la Horra, Vicente Friaza, Rubén Morilla, Juan Delgado, Francisco J Medrano, Robert F Miller, Yaxsier de Armas, Enrique J Calderón
• Journal: Journal of fungi (Basel, Switzerland) (J Fungi (Basel)) Vol. 7 Issue 10 (Oct 13 2021) ISSN: 2309-608X [Electronic] Switzerland
• PMID: 34682277 (Publication Type: Journal Article, Review)